Received Oct 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (QUADRACEL) | SANOFI PASTEUR | 5 | U8383AB | IM / LL |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 2 | Z010383 | IM / RL |
Acute onset of targetoid lesions c/w erythema multiforme following recent administration of Quadracel (DTaP-IPV) vaccine. No evidence of active infection or alternative drug exposure. No significant mucosal involvement or systemic symptoms at this time. EM is a rare, immune-mediated hypersensitivity reaction in children, most commonly triggered by infections, but vaccines are a recognized cause, particularly in the pediatric population. Discussed course is self limited with resolution expected in 7-10 days. Differential diagnosis includes urticaria and Stevens-Johnson syndrome; however, the fixed nature of lesions and absence of extensive mucosal involvement support EM. Mother to monitor for progression or systemic symptoms including mucosal involvement dehydration, etc. Conservative care with tylenol/motrin for pain, and antihistamines for any pruritis. Red flags and return precuations discussed.
human rhinovirus/enterovirus and otitis media
Hx of tympanoplasty. Chronic constipation.
cefdinir 250 mg/5 mL oral suspension
No known